Reporting from ESC 2024 - PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome
New phase 3 data from plozasiran, a small interfering RNA therapy, presented at the European Society of Cardiology (ESC) Congress 2024 indicates there could be hope on the horizon for patients with familial chylomicronemia syndrome (FCS).
The trial, named the PALISADE trial, found use of plozasiran, which targets hepatic production of apolipoprotein C-III and circulating triglycerides, was associated with a statistically significant reduction in triglycerides levels and a lower incidence of pancreatitis relative to placebo therapy. Following the presentation, Arrowhead Pharmaceuticals announced their intent to file a New Drug Application with the US Food and Drug Administration before the end of 2024.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
